These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21449977)
1. The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice. Zanotti I; Maugeais C; Pedrelli M; Gomaraschi M; Salgam P; Calabresi L; Bernini F; Kempen H Br J Pharmacol; 2011 Nov; 164(6):1642-51. PubMed ID: 21449977 [TBL] [Abstract][Full Text] [Related]
2. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet. Song G; Liu J; Zhao Z; Yu Y; Tian H; Yao S; Li G; Qin S Lipids Health Dis; 2011 Jan; 10():8. PubMed ID: 21241519 [TBL] [Abstract][Full Text] [Related]
3. Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. Francone OL; Royer L; Haghpassand M J Lipid Res; 1996 Jun; 37(6):1268-77. PubMed ID: 8808761 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Zhang Y; Zanotti I; Reilly MP; Glick JM; Rothblat GH; Rader DJ Circulation; 2003 Aug; 108(6):661-3. PubMed ID: 12900335 [TBL] [Abstract][Full Text] [Related]
5. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Tanigawa H; Billheimer JT; Tohyama J; Fuki IV; Ng DS; Rothblat GH; Rader DJ Circulation; 2009 Jul; 120(2):160-9. PubMed ID: 19564558 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. Vaisman BL; Klein HG; Rouis M; Bérard AM; Kindt MR; Talley GD; Meyn SM; Hoyt RF; Marcovina SM; Albers JJ J Biol Chem; 1995 May; 270(20):12269-75. PubMed ID: 7744879 [TBL] [Abstract][Full Text] [Related]
7. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI Biochemistry; 2007 Sep; 46(37):10713-21. PubMed ID: 17711302 [TBL] [Abstract][Full Text] [Related]
8. Disruption of the murine lecithin:cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. Ng DS; Francone OL; Forte TM; Zhang J; Haghpassand M; Rubin EM J Biol Chem; 1997 Jun; 272(25):15777-81. PubMed ID: 9188474 [TBL] [Abstract][Full Text] [Related]
9. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726 [TBL] [Abstract][Full Text] [Related]
10. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. Francone OL; Gong EL; Ng DS; Fielding CJ; Rubin EM J Clin Invest; 1995 Sep; 96(3):1440-8. PubMed ID: 7657816 [TBL] [Abstract][Full Text] [Related]
11. Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II. Marzal-Casacuberta A; Blanco-Vaca F; Ishida BY; Julve-Gil J; Shen J; Calvet-Márquez S; González-Sastre F; Chan L J Biol Chem; 1996 Mar; 271(12):6720-8. PubMed ID: 8636092 [TBL] [Abstract][Full Text] [Related]
12. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Tohyama J; Billheimer JT; Fuki IV; Rothblat GH; Rader DJ; Millar JS Atherosclerosis; 2009 Jun; 204(2):418-23. PubMed ID: 18990393 [TBL] [Abstract][Full Text] [Related]
14. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice. Bielicki JK; Forte TM; McCall MR; Stoltzfus LJ; Chiesa G; Sirtori CR; Franceschini G; Rubin EM J Lipid Res; 1997 Nov; 38(11):2314-21. PubMed ID: 9392429 [TBL] [Abstract][Full Text] [Related]
15. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Rotllan N; Llaverías G; Julve J; Jauhiainen M; Calpe-Berdiel L; Hernández C; Simó R; Blanco-Vaca F; Escolà-Gil JC Biochim Biophys Acta; 2011 Feb; 1811(2):104-10. PubMed ID: 21126601 [TBL] [Abstract][Full Text] [Related]
16. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Alexander ET; Weibel GL; Joshi MR; Vedhachalam C; de la Llera-Moya M; Rothblat GH; Phillips MC; Rader DJ Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1496-501. PubMed ID: 19661486 [TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Liao D; Tan H; Hui R; Li Z; Jiang X; Gaubatz J; Yang F; Durante W; Chan L; Schafer AI; Pownall HJ; Yang X; Wang H Circ Res; 2006 Sep; 99(6):598-606. PubMed ID: 16931800 [TBL] [Abstract][Full Text] [Related]
18. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. Alam K; Meidell RS; Spady DK J Biol Chem; 2001 May; 276(19):15641-9. PubMed ID: 11278646 [TBL] [Abstract][Full Text] [Related]
19. Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein A-I variant. Parolini C; Caligari S; Gilio D; Manzini S; Busnelli M; Montagnani M; Locatelli M; Diani E; Giavarini F; Caruso D; Roda E; Roda A; Sirtori CR; Chiesa G Liver Int; 2012 Oct; 32(9):1363-71. PubMed ID: 22845860 [TBL] [Abstract][Full Text] [Related]
20. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Mehlum A; Staels B; Duverger N; Tailleux A; Castro G; Fievet C; Luc G; Fruchart JC; Olivecrona G; Skretting G Eur J Biochem; 1995 Jun; 230(2):567-75. PubMed ID: 7607230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]